Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 Oliver LesterArete Research Not Ranked | Etsy | SELL $43 | ― | ― | Downgraded | Etsy downgraded to Sell from Neutral at Arete | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $60→$65 | ― | 3.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $107→$119 | ― | 0.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $123.7→$143.9 | ― | 21.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $25 | ― | 9.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $70 | ― | 4.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350 | ― | 4.40% | Reiterated | ||||
 | Lumentum Holdings | BUY $105 | ― | -1.60% | Assigned | Lumentum Holdings: Strong Financial Outlook and Market Potential Drive Buy Rating and Increased Price Target | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $157→$192 | ― | 3.40% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $135→$115 | ― | 0.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $118→$115 | ― | 3.00% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $202 | ― | 3.30% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $36 | ― | 6.80% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $95→$110 | ― | 2.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55 | ― | 9.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $71 | ― | 28.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $128→$118 | ― | 0.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85→$55 | ― | 12.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $100 | ― | 4.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $62→$63 | ― | 12.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $100 | ― | 10.20% | Reiterated | ||||
| Insmed | BUY $90→$102 | ― | -5.20% | Reiterated | Analysts' Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (NASDAQ: GDRX) and Insmed (NASDAQ: INSM) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $185 | ― | 6.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $55→$52 | ― | 2.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $40 | ― | 3.80% | Reiterated | ||||
| Prudential Financial | HOLD $117 | ― | -0.20% | Reiterated | Prudential Financial: Balancing Risk Management and Growth Opportunities Amidst Global Challenges | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $53→$56 | ― | 1.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $42 | ― | 2.40% | Reiterated | ||||
| Amplitude | HOLD $12 | ― | -2.30% | Reiterated | Cautious Optimism for Amplitude Amid AI Innovations and Market Challenges | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 7.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $151 | ― | 0.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $149→$147 | ― | 0.90% | Reiterated | ||||
 | Travere Therapeutics | BUY $30 | ― | -16.50% | Initiated | Travere Therapeutics asumed with a Buy at H.C. Wainwright | |||
| Cullinan Management | BUY $22 | ― | -0.90% | Initiated | Cullinan Therapeutics resumed with a Buy at Stifel | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $18→$21 | ― | 0.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $11→$15 | ― | 0.90% | Reiterated | ||||
| Service International | BUY $98 | ― | -0.50% | Reiterated | Strong Performance and Growth Potential: Buy Rating for Service International | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $485→$550 | ― | 12.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $700 | ― | 11.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $556 | ― | 11.00% | Reiterated | ||||
 | Viking Therapeutics | BUY $102 | ― | -0.70% | Reiterated | Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (NASDAQ: VKTX) and Jazz Pharmaceuticals (NASDAQ: JAZZ) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $540→$605 | ― | 6.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $610→$572 | ― | 12.80% | Reiterated | ||||
| UnitedHealth | HOLD $356→$312 | ― | -4.80% | Downgraded | UnitedHealth downgraded to Neutral from Outperform at Baird | |||
 | Summit Therapeutics | SELL $12 | ― | -13.80% | Initiated | Summit Therapeutics initiated with an Underperform at Leerink | |||
 | Amplitude | BUY $16 | ― | -3.80% | Assigned | Amplitude's Strategic Advancements and Growth Potential Highlighted by AI Integration and Mature Experiment Solution | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $51 | ― | 2.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85 | ― | 20.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140→$150 | ― | 5.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $92 | ― | 19.20% | Reiterated |
Rows:
